



~~Im~~possible.  
~~In~~curable.  
~~In~~accessible.

The number of FDA approved cell and gene therapies are increasing.  
*So should your coverage.*

### THE PROBLEM

Cell and gene therapies are here to stay, and with the pipeline of new therapeutic treatments expanding rapidly, the costs associated will soon become insurmountable. This daunting new risk exposure leaves you in the difficult position of either taking on potentially catastrophic claims or shifting some of that risk back onto your clients.

*Putting you...*

#### **Between a rock and a hard place**

Lose clients because of lasering or lose money from million-dollar claims

### THE SOLUTION

Take the proactive approach with Patient Access to Costly and Curative Therapies (PACCT) from OutcomeRx and reintroduce financial predictability to your business and your clients. Differentiate yourself in the market and add additional value to your business block by layering in protections from the claims of today that can amount to more than \$3.5 million per treatment, and the unknown claims of tomorrow.

 **WITHOUT PACCT**  
Your Exposure = Limitless

Reinsurance	Zolgensma <b>\$2.2M</b>
Retained	

 **WITH PACCT**  
Your Exposure = Contained

Reinsurance (possible reduction in premium)	Carveout
Retained	Zolgensma <b>\$2.2M</b>

PACCT currently provides coverage for 7 FDA approved therapies, with plans to include an additional 6-10\*. The latest in medical technologies has turned the impossible into the possible and the incurable into curable. PACCT is now breaking down the cost barrier and taking what was inaccessible and making it accessible for all.

**Want to see your savings potential? Speak with an Expert Today.**

[info@OutcomeRx.com](mailto:info@OutcomeRx.com) | [OutcomeRx.com](http://OutcomeRx.com)

\*Subject to change based on revised estimations of FDA approvals. Zolgensma® is a registered trademark of Novartis AG